Premium
Discovery of potent Covid‐19 main protease inhibitors using integrated drug‐repurposing strategy
Author(s) -
T Muthu Kumar,
K Rohini,
James Nivya,
V Shanthi,
K Ramanathan
Publication year - 2021
Publication title -
biotechnology and applied biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 70
eISSN - 1470-8744
pISSN - 0885-4513
DOI - 10.1002/bab.2159
Subject(s) - drugbank , pharmacophore , protease , drug repositioning , lopinavir , computational biology , repurposing , docking (animal) , ritonavir , drug discovery , telaprevir , drug , chemistry , pharmacology , virology , biology , biochemistry , virus , enzyme , medicine , viral load , ribavirin , hepatitis c virus , antiretroviral therapy , ecology , nursing
The emergence and rapid spreading of novel SARS‐CoV‐2 across the globe represent an imminent threat to public health. Novel antiviral therapies are urgently needed to overcome this pandemic. Given the significant role of the main protease of Covid‐19 for virus replication, we performed a drug‐repurposing study using the recently deposited main protease structure, 6LU7. For instance, pharmacophore‐ and e‐pharmacophore‐based hypotheses such as AARRH and AARR, respectively, were developed using available small molecule inhibitors and utilized in the screening of the DrugBank repository. Further, a hierarchical docking protocol was implemented with the support of the Glide algorithm. The resultant compounds were then examined for their binding free energy against the main protease of Covid‐19 by means of the Prime‐MM/GBSA algorithm. Most importantly, the machine learning‐based AutoQSAR algorithm was used to predict the antiviral activities of resultant compounds. The hit molecules were also examined for their drug‐likeness and toxicity parameters through the QikProp algorithm. Finally, the hit compounds activity against the main protease was validated using molecular dynamics simulation studies. Overall, the present analysis yielded two potential inhibitors (DB02986 and DB08573) that are predicted to bind with the main protease of Covid‐19 better than currently used drug molecules such as N3 (cocrystallized native ligand), lopinavir, and ritonavir.